Atara Biotherapeutics (ATRA) vs Champions Oncology (CSBR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Champions Oncology (CSBR) has outperformed Atara Biotherapeutics (ATRA) over the past year, losing 35.9% versus a loss of 53.7%. Over five years, CSBR leads with a -53.0% price change compared with -98.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $60.4 million), about 1.1 times the size, while Champions Oncology is growing revenue faster (+4.4% vs -6.3%).
On valuation, Atara Biotherapeutics trades at a lower forward P/E (4.0x vs 43.4x for Champions Oncology). Atara Biotherapeutics converts more of its revenue into profit, with a net margin of 27.1% versus -2.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | CSBR |
|---|---|---|
| Share price | $6.33 | $4.34 |
| Market cap | $64.49M | $60.41M |
| 1-day change | -0.16% | -1.36% |
| YTD return | -65.01% | -37.19% |
| 1-year return | -53.73% | -35.89% |
| 5-year return | -98.56% | -52.98% |
| Forward P/E | 3.96 | 43.40 |
| EPS (TTM) | $-1.12 | $-0.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | $59.42M |
| Revenue growth (YoY) | -6.33% | +4.36% |
| Net income (latest FY) | $32.69M | $-1.18M |
| Gross margin | — | 48.00% |
| Operating margin | 29.69% | -1.92% |
| Net margin | 27.07% | -1.98% |
| 52-week high | $19.15 | $8.31 |
| 52-week low | $3.92 | $4.34 |
| Distance from 52-week high | -66.94% | -47.77% |
| Analyst consensus | buy | — |
| Avg. price target upside | +115.96% | — |
| Average volume | 35.46K | 9.71K |
| Shares outstanding | 10.19M | 13.92M |
| Employees | 10 | 214 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CSBR has outperformed ATRA by 17.8 percentage points over the past year.
- Atara Biotherapeutics is more profitable, keeping 27.1 cents of every revenue dollar as net income versus -2.0 cents for Champions Oncology.
- Champions Oncology grew revenue faster in its latest fiscal year (+4.36% vs -6.33%).
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Champions Oncology
CSBR stock →Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice through TumorGraft Technology Platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 214 employees
ATRA vs CSBR FAQ
Which is bigger, Atara Biotherapeutics or Champions Oncology?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $60.41M for Champions Oncology (CSBR).
Which stock has performed better over the past year, ATRA or CSBR?
CSBR returned -35.89% over the past 12 months, compared with -53.73% for ATRA (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Champions Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.